Biocon Ltd
Company Profile
Business description
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
Contact
20th KM, Hosur Road
Electronics City
BengaluruKA560100
INDT: +91 8028082808
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
9,805
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,674.90 | 172.70 | -2.20% |
| CAC 40 | 7,017.50 | 257.45 | -3.54% |
| DAX 40 | 20,010.11 | 631.61 | -3.06% |
| Dow JONES (US) | 37,822.40 | 2,723.53 | -6.72% |
| FTSE 100 | 7,802.51 | 252.47 | -3.13% |
| HKSE | 19,973.09 | 2,876.72 | -12.59% |
| NASDAQ | 15,556.05 | 994.56 | -6.01% |
| Nikkei 225 | 32,747.68 | 1,032.90 | -3.06% |
| NZX 50 Index | 11,891.44 | 333.84 | -2.73% |
| S&P 500 | 5,041.94 | 32.14 | -0.63% |
| S&P/ASX 200 | 7,480.80 | 187.00 | -2.44% |
| SSE Composite Index | 3,113.34 | 16.77 | 0.54% |